Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer

Paul Mathew, Christopher J. Logothetis, Pauline Y. Dieringer, Isan Chen, Lance C. Pagliaro, Benjamin N. Bekele, Xian Zhou, Danai D. Daliani

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Background: This is a phase I/II trial of thalidomide with estramustine and paclitaxel in men with androgen-independent prostate cancer (AIPC) who underwent previous chemotherapy. Patients and Methods: Men with progressive AIPC were treated with oral thalidomide (200 mg, 400 mg, or 600 mg daily), intravenous paclitaxel (100 mg/m2 over 3 hours on days 3 and 10), and oral estramustine (140 mg 3 times daily on days 1-5 and days 8-12) every 21 days. Results: Phase I: first cycle dose-limiting toxicity occurred in 0 of 3 patients at 200 mg thalidomide daily, 0 of 3 at 400 mg daily, and 1 of 3 at 600 mg daily (the designated maximum tolerated dose). Phase II: twenty-nine of 38 evaluable patients (76%; 95% confidence interval, 67%-87%) experienced a 50% decrease in prostate-specific antigen level. Five of 18 patients (28%) with measurable disease exhibited an objective response. Nine of 14 patients (64%) with disease refractory to previous taxane therapy had 50% decreases in prostate-specific antigen level. Grade 3/4 adverse events included neutro-penia (9 of 39 [23%]), fatigue (9 of 39 [23%]), dyspnea (8 of 39 [21%]), and thromboembolic events (7 of 39 [18%]). Cumulative dose-limiting toxicity rates were minimal (13%) with thalidomide at 200 mg daily. Conclusion: The profile of activity of thalidomide/paclitaxel/estramustine in taxane-refractory AIPC warrants further investigation.

Original languageEnglish (US)
Pages (from-to)144-149
Number of pages6
JournalClinical Genitourinary Cancer
Issue number2
StatePublished - 2006


  • Angiogenesis
  • Immunomodulatory agent
  • Taxanes
  • Thromboembolic events

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer'. Together they form a unique fingerprint.

Cite this